je.st
news
Tag: congress
DENSO to Exhibit at the 22th ITS World Congress Bordeaux 2015
2015-10-02 12:31:11| Industrial Newsroom - All News for Today
KARIYA, JAPAN, - Global automotive supplier DENSO Corporation will exhibit at the 22nd World Congress on Intelligent Transport Systems in Bordeaux, France, October 5-9. DENSO will present under the theme "Technology to keep people safe wherever they drive-Everyday Confidence, Extraordinary Safety." DENSO will...
Tags: world
exhibit
congress
bordeaux
Congress Clears 6-Month FAA Stopgap Measure
2015-09-30 03:21:27| ENR.com: Headline News
President Obama is expected to sign the bill before current authorization lapses.
Tags: measure
congress
clears
faa
Showtime or Showdown as Congress Considers Tax Issues?
2015-09-28 16:51:00| National Real Estate Investor
There is a myriad of pending tax issues falling victim to a Congress that still claims to have broad tax reform on the agenda, but never seems to find the right time to explore it. read more
Tags: issues
tax
congress
considers
3M Shares New Products and Safety Best Practices at NSC Congress & Expo
2015-09-28 12:31:15| Industrial Newsroom - All News for Today
Experts on hand for new product demos and professional development sessions ST. PAUL, Minn. Working to create a safer world for workers, 3M has strengthened its core personal protective equipment (PPE) and expanded its safety services offerings in time for the annual National Safety Council (NSC) Congress and...
Tags: products
safety
practices
shares
New Data from KEYNOTE-028, Mercks Trial Evaluating KEYTRUDA (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress
2015-09-27 13:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Findings Show Anti-Tumor Activity for KEYTRUDA in Two Gastrointestinal Cancers KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new findings from the KEYNOTE-028 Phase 1b study, the clinical trial investigating the use of the companys anti-PD-1 therapy, KEYTRUDA (pembrolizumab) in multiple, difficult-to-treat cancers. Data from this trial, to be presented at the European Cancer Congress (ECC) in Vienna, Austria, Sept. Language: English Contact: MerckMedia Contacts:Pamela Eisele, 267-305-3558An Phan, 908-255-6325orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
range
types
presented
Sites : [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] next »